Medical technology company Scivita Medical Technology Co. and Boston Scientific have officially signed a strategic agreement for Scivita's Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership in the commercialisation, marketing and promotion of Scivita's Single-Use Percutaneous Choledochoscope in China.

Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation further broadens its market penetration of its Single-Use Percutaneous Choledochoscope. Through the strong alliance with Boston Scientific, the penetration rate of the Single-Use Percutaneous Choledochoscope in China is expected to increase benefiting more hospitals and patients.

As a result of the growing demands of mitigating the risks of cross-contamination and hospital-acquired diseases, particularly amid the outbreak of COVID-19 pandemic, the global single-use videoscope market is also rapidly growing. The global market value of single-use videoscope was $0.5 billion in 2020, and is estimated to increase to $9.2 billion in 2030, according to Frost & Sullivan. Scivita Medical's single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union (EU), Japan and other countries and regions.